Therapeutic approaches to reducing the LDL- and HDL-associated risks of coronary heart disease

Current Opinion in Lipidology

Volumn 11, Issue 6, 2000, Pages 567-570

  Thompson, Gilbert R ^a   Barter, Philip J ^b  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b ROYAL ADELAIDE HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BEZAFIBRATE; CHOLESTEROL ESTER TRANSFER PROTEIN; COLESTYRAMINE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRAVASTATIN;

ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CLINICAL TRIAL; HEART INFARCTION; HUMAN; HYPERCHOLESTEROLEMIA; ISCHEMIC HEART DISEASE; NONHUMAN; PRIORITY JOURNAL; RABBIT; REVASCULARIZATION; REVIEW; STROKE;

ORYCTOLAGUS CUNICULUS;

EID: 0033673858     PISSN: 09579672     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041433-200012000-00001     Document Type: Review

References (26)

1. The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease
2. The Lipid Research Clinics Coronary Primary Prevention Trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering
3. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease
4. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels
5. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels
6. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia
7. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels
8. Effect of statins on risk of coronary disease: A meta-analysis of randomised controlled trials
9. Reductase inhibitor monotherapy and stroke prevention
10. The effect of aggressive lowering of low-density lipoprotein cholesterol levels low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts
11. Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease
12. Inhibition of atherosclerosis development in cholesterol-fed human apolipoprotein A-I-transgenic rabbits
13. Apolipoprotein Al transgene corrects apolipoprotein E deficiency-induced atherosclerosis in mice
14. Human apolipoprotein A-I gene expression increases high density lipoprotein and suppresses atherosclerosis in the apolipoprotein E-deficient mouse
15. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol
16. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease. The Bezafibrate Infarction Prevention (BIP) Study
17. Increased coronary heart disease in Japanese-American men with mutations in the cholesteryl ester transfer protein gene despite increased HDL levels
18. A low prevalence of coronary heart disease among subjects with increased high density lipoprotein cholesterol levels, including those with plasma cholesteryl ester transfer protein deficiency
19. Effect of antisense oligonucleotides against cholesteryl ester transfer protein on the development of atherosclerosis in cholesterol-fed rabbits
20. A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits
21. Vaccine-induced antibodies inhibit CETP activity in vivo and reduce aortic lesions in a rabbit model of atherosclerosis
22. Severe atherosclerosis in transgenic mice expressing simian cholesteryl ester transfer protein
23. Increased atherosclerosis in apoE and LDL receptor gene knock-out mice as a result of human cholesteryl ester transfer protein transgene expression
24. Cholesteryl ester transfer protein corrects dysfunctional high density lipoproteins and reduces aortic atherosclerosis in lecithin cholesterol acyltransferase transgenic mice
25. Decreased early atherosclerotic lesions in hypertriglyceridemic mice expressing cholesteryl ester transfer protein transgene
26. CETP and atherosclerosis